

ABOVE: Cerclage after Caesarean

Submission date 17/05/2024	Recruitment status Recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 17/05/2024	Overall study status Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 21/01/2026	Condition category Pregnancy and Childbirth	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Recent studies have shown that if a woman has had a caesarean section in labour (when the cervix is opening) she is more likely to have a premature baby in a future pregnancy. In women who have had an in-labour caesarean section there is a 5-10% chance of a preterm birth in a subsequent pregnancy.

For women who have had an in-labour caesarean section, which was then followed by a preterm birth or mid-trimester loss, early birth is even more likely in subsequent pregnancies. Currently it is not known which treatments are most effective to stop this happening.

These women should be referred to specialist preterm clinics, which will offer them ultrasound monitoring of the length of their cervix, and they may or may not also be offered a cervical cerclage, although there are currently no national guidelines about this. This is a small surgical procedure where a stitch is placed around the cervix through the vagina (transvaginal cerclage). A cerclage can also be placed higher up, through an abdominal procedure involving a cut in the tummy (transabdominal cerclage). This procedure is a longer operation with more recovery time and means that any future babies will need to be born by caesarean section.

Both types of cerclage are offered as standard care to women at high risk of preterm birth. Although transvaginal cerclages are more straightforward, transabdominal cerclages might be more effective because they are above any damage that might have been caused during a previous caesarean section.

Who can participate?

Women who have had a preterm birth or mid-trimester loss (a loss between 14 and 24 weeks of pregnancy) after a previous caesarean section in labour

What does the study involve?

Participants will be allocated to one of two treatments: a vaginally-placed cervical stitch or an abdominally-placed cervical stitch, performed before 14 weeks of pregnancy. Some women will join the study before pregnancy, in this group the abdominally-placed stitch will be sited before they get pregnant and the vaginal stitch before 14 weeks in the next pregnancy.

With both stitches participants are followed up in a prematurity clinic with regular transvaginal scanning. If the cervix becomes short participants may be admitted to hospital or offered other treatments (such as a steroid injection to help the baby's lungs mature, and/or putting in an additional stitch if the cervix opens). These may be offered if there is a high chance the baby may be born very early.

The researchers will ask your permission to look at participants' medical notes after delivery to find out what happened. They may also save some scan images of the cervix taken in the prematurity clinic.

In addition to evaluating the two cerclages, we are inviting women who have not been randomised in this study to take part in this observational group. We will be asking if they are happy for us to collect information about what happens to them in this pregnancy and their baby after birth.

What are the possible benefits and risks of participating?

Taking part in the study may not have any direct benefit to participants now. However, the results of this study might help to improve care in any future pregnancies as well as other women, and to reduce the number of babies being born too early.

Having a cervical stitch inserted is a relatively common procedure and is known to help some women. Risks of both treatments include post-operative pain, infection and bleeding. The uncommon risks (occurring in 1 out of 1000) include tearing of the cervix or bladder. The obstetrician would generally be able to repair any tearing to the cervix immediately. A tear to the bladder would require another operation by a urologist (a medical doctor with specialist training in problems of the urinary tract). Both would require a few extra days in hospital. If the doctor is worried about infection, a swab may be taken from the vagina and, if there is evidence of infection, participants may be given a course of antibiotics. While it is likely that either of the cerclages will reduce the chance of miscarriage or preterm birth, they will not entirely eliminate the possibility.

Where is the study run from?

St Thomas' Hospital (UK)

When is the study starting and how long is it expected to run for?

October 2023 to May 2027

Who is funding the study?

1. Action Research Medical (UK)
2. Borne (UK)

Who is the main contact?

above-study@kcl.a.c.uk

Contact information

Type(s)

Public, Scientific

Contact name

Prof Andrew Shennan

ORCID ID

<https://orcid.org/0000-0001-5273-3132>

Contact details

Women's and Children's Department
10th Floor
St Thomas Hospital Westminster

Bridge Road
London
United Kingdom
SE1 7EH
+44 (0)20 7188 7188
andrew.shennan@kcl.ac.uk

Type(s)

Public, Scientific

Contact name

Dr Laura van der Krogt

ORCID ID

<https://orcid.org/0009-0004-2040-0375>

Contact details

Women's and Children's Department
10th Floor
St Thomas Hospital
Westminster Bridge Road
London
United Kingdom
SE1 7EH
+44 (0)20 7188 7188
laura.c.van_der_krogt@kcl.ac.uk

Type(s)

Public, Scientific

Contact name

Dr Jenny Carter

Contact details

Women's and Children's Department
10th Floor
St Thomas Hospital
Westminster Bridge Road
London
United Kingdom
SE1 7EH
+44 (0)20 7188 7188
jenny.carter@kcl.ac.uk

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

Integrated Research Application System (IRAS)

327879

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

CPMS 59777, IRAS 327879

Study information

Scientific Title

Cerclage after Caesarean: a randomised controlled trial to assess the optimal preventative management for preterm birth secondary to caesarean section damage (ABOVE)

Acronym

ABOVE

Study objectives

Transabdominal cerclage (TAC) will be more effective than transvaginal cerclage (TVC) in reducing mid-trimester pregnancy loss (MTL) and spontaneous preterm birth (PTB) in women with experience of MTL/spontaneous preterm birth (sPTB) after in-labour caesarean section (CS).

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approval 15/05/2024, North West - Preston Research Ethics Committee (2 Redman Place Stratford, London, E20 1JQ, UK; +44 (0)2071048364; preston.rec@hra.nhs.uk), ref: 24 /NW/0093

Study design

Randomized; Interventional; Design type: Treatment, Surgery

Primary study design

Intentional

Study type(s)

Prevention

Health condition(s) or problem(s) studied

Preterm birth secondary to caesarean section

Interventions

ABOVE is a multi-centre randomized controlled trial comparing TAC or TVC as a preventative strategy for sPTB in women with a history of sPTB or MTL after an in-labour caesarean section.

Participants will be allocated to either Group A or Group B depending on whether they are already pregnant or planning a pregnancy. The trial is separately powered for these two groups; Group A: in pregnancy and Group B: pre-conception.

160 participants with complete data in total (80/group) with a history of term CS in labour, followed by a subsequent pregnancy loss or sPTB (defined as MTL between 14+0-23+6 weeks or sPTB <30 weeks), either planning a pregnancy, or <14 weeks pregnant <14 weeks pregnant (Group A) or planning a pregnancy (Group B), will be recruited. To allow for loss to follow up, and Group B participants not becoming pregnant within the 18 recruitment period.

Eligible women referred to specialist preterm birth services, either for pre-pregnancy counselling or pregnancy surveillance, will be offered the opportunity to take part in this trial. Pregnant participants (<14 weeks gestation) will be allocated to Group A, while women planning a pregnancy will be allocated to Group B.

Participants will be randomised (1:1) through the ABOVE trial database, which will be hosted within the Medscinet PCN Database (<https://www.medscinet.net/ukpcn>; REC reference 22/ES/01; IRAS 308157). Women will be randomised to one of the two preventative treatments: 1) TAC, or 2) TVC

It is important to separately evaluate pre-conception and in-pregnancy TACs. The suture can be placed higher pre-conception and this may provide better support around scar weakness. Efficacy could therefore be different in these populations so separately powered trials are planned.

Once randomisation has occurred, the allocated procedure will be arranged. A cervical cerclage will be inserted. The choice of cerclage insertion technique and anaesthesia will be at the local clinician's discretion with all details recorded on the trial database. Participants in Group A will have the cerclage (TAC or TVC) inserted prior to 14 weeks' gestation, usually under regional anaesthetic. Group B participants allocated to TAC will have the procedure placed pre-conceptually and those allocated to TVC will have it placed before 14 weeks' gestation (depending on the time point at study entry and randomisation). TACs are performed as an open or laparoscopic procedure under either regional or general anaesthetic, requiring an inpatient stay of up to 3 days. TVCs will be performed at the participant's local maternity unit with the insertion technique and anaesthesia according to the clinician's discretion and local practices. TACs will usually remain in-situ (to support any future pregnancies) while TVCs are removed at around 37 weeks' gestation. TACs are more specialised procedures and so, if unavailable locally, they may be carried out in tertiary specialist units. The time frame between randomisation and study procedure is flexible from site to site, depending on theatre list availability, although all procedures must be carried out before 14 weeks' gestation.

There will be no additional research visits, and all preterm care will continue according to local participating site protocols.

Demographic, ongoing preterm surveillance (including cervical length measurements) and outcome data will be collected by recruiting sites from hospital electronic records and entered directly into the study database. Participant identifiers (initials, date of birth, hospital and NHS number) are kept on a separate but linked Medscinet database which is only accessible to authorised site users.

Intervention Type

Procedure/Surgery

Primary outcome(s)

The occurrence of mid-trimester pregnancy loss or spontaneous preterm birth before 30 weeks of gestation, collected from the patient's medical records

Key secondary outcome(s)

Maternal:

1. Admission to hospital for symptoms of threatened preterm labour
2. Administration of antenatal corticosteroids for fetal lung maturation
3. Administration of magnesium sulphate for fetal cerebral protection.
4. Transfer to other hospitals for neonatal cot availability (in-utero transfer)
5. Time between intervention and delivery
6. Requirement for additional emergency/rescue cerclage
7. Serious complications occurring as a result of trial intervention: bladder injury, bowel injury, intraoperative rupture of membranes, cervical tear, hysterectomy
8. Maternal sepsis
9. Admission to ITU
10. Maternal death

Neonatal:

1. Gestation at birth
2. Birthweight
3. Apgar scores (if available)
4. Days before discharge home (up to 28 days)
5. Admission to neonatal unit
6. Neonatal infection
7. In utero fetal death after 14 weeks
8. Stillbirth
9. Neonatal death

Collected from the patient's medical records at time of birth unless stated otherwise

Completion date

01/05/2027

Eligibility

Key inclusion criteria

Women will be eligible for the trial if they are:

1. Willing and able to give informed consent
2. Aged 16 years or above
3. Have had a previous term in-labour caesarean section (between 4 and 10 cm dilated) followed by an MTL (> 14 weeks) or preterm birth (<30 weeks)
4. Pregnant, but will be less than 14+0 weeks' gestation at the time of the allocated intervention (Group A) OR
5. Not yet pregnant but considering a further pregnancy (Group B)

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Mixed

Lower age limit

16 years

Upper age limit

65 years

Sex

Female

Total final enrolment

0

Key exclusion criteria

Potential participants will not be eligible for the trial if:

1. They are more than 14+0 weeks pregnant at the time of randomisation (as insertion of TAC is associated with higher risk beyond this gestation)
2. They already have a cerclage or (Arabin) pessary in situ
3. They are not planning another pregnancy
4. They have a history of preterm birth (spontaneous/iatrogenic) prior to the term emergency section
5. They are pregnant and expecting more than one baby (multiple pregnancy)

Date of first enrolment

01/07/2024

Date of final enrolment

01/05/2027

Locations**Countries of recruitment**

United Kingdom

England

Study participating centre

St Thomas' Hospital

Westminster Bridge Road

London

England

SE1 7EH

Study participating centre

Uclh

250 Euston Road
London
England
NW1 2PQ

Study participating centre**Liverpool Womens Hospital**

Crown Street
Liverpool
England
L8 7SS

Study participating centre**The Royal Victoria Infirmary**

Queen Victoria Road
Newcastle upon Tyne
England
TS1 4LP

Study participating centre**Birmingham Women's and Children's NHS Foundation Trust**

Steelhouse Lane
Birmingham
England
B4 6NH

Study participating centre**Royal United Hospital**

Combe Park
Bath
England
BA1 3NG

Study participating centre**University Hospital Coventry**

Clifford Bridge Road
Coventry
England
CV2 2DX

Study participating centre

Barnet Hospital

Wellhouse Lane

Barnet

England

EN5 3DJ

Study participating centre

Royal London Hospital

Whitechapel

London

England

E1 1BB

Study participating centre

Conquest Hospital

The Ridge

St. Leonards-on-sea

England

TN37 7RD

Study participating centre

Manchester University Hospital NHS Ft (hq)

Oxford Road

Manchester

England

M13 9WL

Study participating centre

South Tyneside and Sunderland NHS Foundation Trust

Sunderland Royal Hospital

Kayll Road

Sunderland

England

SR4 7TP

Sponsor information

Organisation

King's College London

ROR

<https://ror.org/0220mzb33>

Funder(s)

Funder type

Charity

Funder Name

Action Medical Research; Grant Codes: GN2967

Alternative Name(s)

action medical research for children, actionmedres, The National Fund for Research into Crippling Diseases, AMR

Funding Body Type

Private sector organisation

Funding Body Subtype

Trusts, charities, foundations (both public and private)

Location

United Kingdom

Funder Name

Borne

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	Group A version 3.0		17/05/2024	No	Yes

[Participant information sheet](#)

Group B
version 3.0

17/05/2024 No

Yes